Lymphie, Lymphie, Lymphie! Oi, Oi, Oi!
Are you an Australian living with secondary lymphedema?
Researchers in Australia are working to understand breast cancer-related lymphedema and study the effectiveness of a new, investigational treatment — and you may be able to help.
The clinical trial is for an investigational new medication to treat lymphedema in patients who previously had breast cancer. The drug, LYT-100 (deupirfenidone), is an anti-inflammatory and anti-fibrotic small molecule administered in capsule form.
The study is randomized and double-blind, which means participants will be randomly assigned to receive either the drug or a placebo, and neither the participants nor the researchers know who is receiving which.
The study will run over a 48-week period and include 26 weeks of treatment. The research is ongoing in three states in Australia; enrolled participants will be making regular visits to one of these study sites.
Recruitment is currently open to participants in Australia. They’re looking for men and women who:
- Are between 18-80 years old
- Are between 6 months to 15 years since breast surgery (excluding Fine Needle Aspiration [FNA])
- Are at least 3 months since completion of radiotherapy or chemotherapy at the time of screening
- Have a diagnosis of primary breast cancer
- Have had upper limb lymphedema for at least three months, but for no longer than four years
Interested in participating?
Research studies help bring new options to patients. A few years ago I met Barbara H., a woman living with cancer-related lymphedema. At the time, she was enrolled in a clinical trial investigating a different pharmaceutical treatment for lymphedema, and we had an invigorating conversation about what participating in a research study meant to her.
“Without drug trials we can’t move forward and find help,” she had said. “So if I have to endure a few tests, that’s OK with me.”
If this resonates with you, this trial may be an opportunity for you.
Check your eligibility with this quick pre-screener from Leapcure, an organization that connects patients with research trials. If you’re a good fit, the Leapcure team will get in touch with you to walk you through the next steps in the enrollment process and connect you with a nearby trial site in Australia.
Your participation could support other patients in your position and play a role in advancing research for the whole lymphedema community. Thank you for considering!
I am not affiliated with Leapcure nor this study. However, if you have any questions or would like to learn more about the study, you are welcome to call Leapcure at +61 1800 577 313.
More about Leapcure
Leapcure is an organization that works with over 4,500 patient advocacy groups around the world to connect patients with research trials. Their work helps further the patient voice in research and ensures access to clinical trials for patients and individuals of diverse backgrounds and communities. The Leapcure team are excited to be part of this important research, and look forward to welcoming you!